Actively Recruiting
Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Led by Centre Hospitalier St Anne · Updated on 2024-11-07
200
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.
CONDITIONS
Official Title
Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Affiliated with a social security or other social protection scheme
- Diagnosed with schizophrenia according to DSM-5 (code F20)
- Stable condition without specific duration requirement
- Main treatment with risperidone, paliperidone, aripiprazole, or olanzapine (oral or long-acting injectable)
- May have complementary antipsychotic treatment for anxiolytic or sedative purposes (chlorpromazine, loxapine, or cyamemazine)
- Able to speak and read French
- Able to perform speech evaluations
- Able to answer questionnaires on a smartphone
- May be under curatorship or guardianship
- Provides informed consent personally or via legal representative if under curatorship or guardianship
You will not qualify if you...
- Having a condition that impairs French language ability
- Having a neurological disease such as multiple sclerosis, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders
- Currently treated with lithium salts
- Currently on anti-epileptic treatment
- Participation in another study involving medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris
Paris, Paris, France, 75014
Actively Recruiting
2
Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences
Paris, France, 75014
Not Yet Recruiting
Research Team
P
Pierre De Maricourt, Dr
CONTACT
P
Philippe Domenech, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here